Written Question·Department of Health and Social Care·UIN HL16087
Blood Cancer: Medical Treatments
Tabled: 26 March 2026
Question
To ask His Majesty's Government what assessment they have made of the consequences for patients with mantle cell lymphoma of NICE’s decisions not to recommend (1) brexucabtagene autoleucel, and (2) acalabrutinib with bendamustine and rituximab; and what s